Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 7/20 | 0.76 |
| ▸ | CACNA1H | O95180 | 7/20 | 0.76 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.76 |
| ▸ | CNR2 | P34972 | 3/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3041292 | 1.00 | CACNA1I (0.76) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL23328328 | 0.88 | CACNA1I (0.62) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| Suvecaltamide SCHEMBL1065999 | 0.86 | CACNA1I (1.00) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| Suvecaltamide SCHEMBL21828396 | 0.86 | CACNA1I (1.00) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| Suvecaltamide SCHEMBL29791943 | 0.86 | CACNA1I (1.00) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL12999615 | 0.81 | CACNA1I (0.52) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL2140640 | 0.80 | CACNA1I (0.52) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL2140629 | 0.80 | CACNA1I (0.52) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL3030405 | 0.79 | CACNA1H (0.60) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL3037471 | 0.79 | CACNA1H (0.60) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216816-A1 | PYRAZINYL AMIDE-T TYPE CALCIUM CHANNEL ANTAGONISTS | BARROW JAMES C | 2010-08-26 | — | — | US | claimed |
| EP-2211864-A1 | PYRAZINYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-08-04 | — | — | EP | claimed |
| WO-2009054982-A1 | PYRAZINYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | claimed |
| US-20100216816-A1 | PYRAZINYL AMIDE-T TYPE CALCIUM CHANNEL ANTAGONISTS | BARROW JAMES C | 2010-08-26 | — | — | US | disclosed |
| US-20100216816-A1 | PYRAZINYL AMIDE-T TYPE CALCIUM CHANNEL ANTAGONISTS | BARROW JAMES C | 2010-08-26 | — | — | US | disclosed |
| US-20100216816-A1 | PYRAZINYL AMIDE-T TYPE CALCIUM CHANNEL ANTAGONISTS | BARROW JAMES C | 2010-08-26 | — | — | US | disclosed |
| EP-2211864-A1 | PYRAZINYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009054982-A1 | PYRAZINYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009054982-A1 | PYRAZINYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216816-A1 | PYRAZINYL AMIDE-T TYPE CALCIUM CHANNEL ANTAGONISTS | CACNA1G, CACNA1H, CACNA1I | CACNA1I 3/4885CACNA1H 2/4885CACNA1G 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.